{
  "units": [
    {
      "title": "Methods",
      "text": "methods are not quite at single-cell resolu- from two individuals (Extended Data Fig. 3a–e). After integrattion and rely on the computational integration of coupled single-cell ing single-cell transcriptomics and Visium data using our recently\n(or single-nucleus) transcriptomes to achieve this level of detail18–20. developed cell2location algorithm18, cell states were mapped to the\nThese genomic technologies are the basis of the Human Cell Atlas endometrium and/or the myometrium. We identify specific perivasinitiative, which aims to map all cells in the human body21. cular cells: PV MYH11 are characteristic of myometrium while PV\n In this study, by using single-cell and spatial transcriptional STEAP4 are only present in the endometrium (Fig. 1g and Extended\nprofiling, we interrogate the cellular states and spatial localization Data Fig. 3f). In addition, we find that fibroblasts C7 are enriched\nof human endometrial cells during the proliferative and secretory in the basal layer of the endometrium in both the proliferative and\nphases of the menstrual cycle in women of reproductive age. We secretory phases (Fig. 1h,i and Extended Data Fig. 3f).\ndevelop CellPhoneDB v.3.0 to measure intercellular communica- Altogether, our analysis yields a comprehensive catalog of the\ntion taking into account spatial coordinates of cells and use this major subsets of uterine cells together with their cellular position\ntool to define cell signaling in both lumenal and glandular epi- in endometrium and myometrium. We have made an open-source\nthelial microenvironments. We define a complementary role for web server available at www.reproductivecellatlas.org.\nWNT and NOTCH signaling in regulating differentiation toward\nthe two main epithelial lineages (ciliated and secretory). We pro- Spatiotemporal characterization of proliferative epithelium. We\nfile three-dimensional endometrial organoids at single-cell resolu- next focused on the two main lineages of endometrial epithelial\ntion to characterize their hormonal responses in vitro and design a cells, secretory and ciliated, across the menstrual cycle and analyzed\ncomputational toolkit to compare the results with those observed these subsets individually (Fig. 2a). Epithelial cells are classified into\nin vivo to benchmark this model system. Finally, by modulating four main groups based on their marker expression: (1) SOX9 pop-\nWNT and NOTCH pathways in the organoid cultures, we develop ulations, enriched in the proliferative phase and expressing genes\nlineage-specific endometrial epithelial cells and define the molecu- characteristic of rising estrogen levels (MMP7, ESR1); (2) ciliated\nlar events involved in their response to ovarian hormones. cells (PIFO, TPPP3); (3) lumenal cells (LGR5); and (4) glandular\n cells (SCGB2A2) (Fig. 2b–d and Extended Data Fig. 4a,b). A frac-\nResults tion of the glandular epithelial cells express molecules characteristic\nA single-cell map of the full-thickness human uterus. To gener- of uterine milk in the secretory stage (PAEP, CXCL8).\nate a cellular map of the human endometrium that accounts for the With our integrative scRNA-seq maps, we can now resolve\ntemporal and spatial changes across the menstrual cycle, uterine three clusters within the SOX9 population: (1) SOX9+LGR5+ cells,\nsamples were analyzed by single-cell transcriptomics—single-cell expressing KRT17 and WNT7A; (2) SOX9+LGR5− cells, expressing\nRNA sequencing (scRNA-seq) and single-nucleus RNA sequenc- IHH; and (3) proliferative SOX9+ cells, including both LGR5+ and\ning (snRNA-seq)—alongside spatial transcriptomics methods (10x LGR5− cycling cells (that is, cells in G2M/S phase). By integrating\nGenomics Visium slides and high-resolution microscopy) (Fig. 1a scRNA-seq and Visium data (Fig. 2e and Extended Data Fig. 4c), we\nand Extended Data Fig. 1a). Two different types of samples from define specific spatial coordinates for these SOX9 subsets: (1) nonwomen of reproductive age were integrated in our analysis: endo- cycling SOX9+LGR5+ cells are enriched in the surface epithelium; (2)\nmetrial biopsies from live donors screened for potential endome- noncycling SOX9+LGR5− cells are located in the basal glands; and\ntrial disorders (n = 3) and the whole endometrium with attached (3) cycling SOX9+ cells map to glands in the regenerating superficial\nsubjacent myometrium from the uteri of donors who died of non- layer. Single-molecule fluorescence in situ hybridization (smFISH)\ngynecological causes (n = 6) (Supplementary Table 1). This latter with RNAscope probes shows higher expression of the proliferative\napproach allows sampling of the endometrial basal layer and myo- marker MKI67 in the superficial layer of the endometrium durmetrium, which are absent from endometrial biopsies. ing the proliferative phase, validating Visium data (Extended Data\n We were able to generate a uterine map of 98,568 cells from 15 Fig. 5a). We also validated the presence of the markers LGR5 and\nindividuals by integrating our dataset with previous scRNA-seq data WNT7A, characteristic of the SOX9+LGR5+ cells present in surface\nobtained from superficial endometrial biopsies22 (Fig. 1b, Extended epithelium during the proliferative phase (Fig. 2f and Extended\nData Fig. 1b–f and Supplementary Table 2). We identify 14 clusters Data Fig. 5b,c). SOX9 and LGR5 are expressed in stem cells/prothat were assigned cell identity based on their expression of known genitors in several tissues including gut, kidney, skin and ovaries\nmarkers (Extended Data Fig. 1g). These clusters can be grouped and may label similar populations in the human endometrium24–29.\ninto five main cellular categories: (1) immune (lymphoid and Ciliated cells are present in both the proliferative and secretory\nmyeloid); (2) epithelial (SOX9+, lumenal, glandular and ciliated); phases, but, as expected, PAEP secretory cells are only present fol-\n(3) endothelial (arterial and venous); (4) supporting—perivascular lowing ovulation (Fig. 2b,c and Extended Data Fig. 4b). This indicells (PV STEAP4 and PV MYH11), smooth muscle cells and fibro- cates that estrogen alone can induce ciliary differentiation, while\nblasts expressing C7 (fibroblasts C7); and (5) stromal—nondecidu- secretory differentiation depends on the addition of progesterone.\nalized endometrial (eS) and decidualized endometrial (dS). SOX9+ During the proliferative phase, in addition to the FOXJ1, PIFO,\nepithelial cells and eS are characteristic of the regenerating prolif- TP73 ciliated population, we define a distinct subset of preciliated\nerative phase (Fig. 1c). Subclustering of immune cells resolves their cells that express MUC12, HES6 and cell cycle genes (CDC20B,\nheterogeneity, including identification of the three uterine natural CCNO) (Fig. 2d).\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1699\n\nArticles NaTurE GEnETICS\n\n a b c\n scRNA-seq; proliferative & secretory phases Menstrual phase\n n = 98,568\n\n\n sn/scRNA-seq Immune\n Visium Proliferative Secretory\n Myeloid\n Endometrial biopsy\n\n\n Lymphoid Stromal\n\n\n UMAP2\n Basal layer Functional layer\n Endometrium\n\n\n eS\n Uterine biopsy\n\n\n Epithelial Supporting\n UMAP1 Proliferative\n Gland dS\n Secretory\n d\n uSMC\n Lumen fibro_C7 Vein Immune cycling uNK2\n Myometrium\n\n\n SOX9 uNK1\n PV_STEAP4 Art uM2\n uNK3\n\n\n UMAP2\n 0 5 14 28 mast\n Cilia Endothelial uM1 pb_NK\n B cells\n PV_MYH11 DCs CD8_T\n UMAP1 CD4_T\n\n\n UMAP2\n ILC3\n\n\n UMAP1\n\n e f g\n snRNA-seq; proliferative phase\n Early secretory (A30)\n n = 27,426\n\n Epithelial PV MYH11\n SOX9 early dS Epi SOX9\n Endothelial\n SOX9 late SOX9\n eS eS Lumenal 0 137 275\n early\n Immune SOX9\n Mac Lymphatics\n fibro C7 late Glandular PV STEAP4\n Lymph\n mast Fibro C7\n Vein\n plasma 0 74 149\n B cells Art\n uSMC uSMC Ciliated\n PV_STEAP4 PV_MYH11 mast\n plasma B uSMC\n fibro_C7 PV STEAP4 lymphoid\n Supporting lymphatic\n PV STEAP4 Lymphoid 0 541 1,028\n uSMC myeloid\n PV MYH11\n eS PV MYH11 Myeloid\n UMAP2\n\n\n artery vein\n Stromal\n Endothelial artery Endothelial vein\n 1,000 µm\n\n\n UMAP1\n S)\n )\n e eS\n\n\n (d\n as a (\n\n\n e a\n as m\n\n\n h i\n ph m\n\n\n ph tro\n e ro\n\n\n y s\n tiv st\n\n\n or d\n ra ial\n\n\n et ize\n\n\n Mid proliferative (A13) Early secretory (A30)\n ife tr\n 7\n\n\n cr al\n ol e\n C\n\n\n a\n\n\n se idu\n pr om\n m\n o\n br\n\n\n ro\n\n\n ec\n d\n En\n Fi\n\n\n St\n\n\n D\n\n\n Fibro C7\n eS\n dS\n ACTA2\n C7\n OGN\n IGF1\n PCOLCE\n MMP11\n CRABP2\n ECM1\n FOXO1\n IL15\n CFD\n CEBPB\n PDGFRA\n\n\n Fraction of cells\n Mean expression in group (%)\n in group Fibroblast C7 eS 1,000 µm Fibroblast C7 eS 1,000 µm\n 100%\n 80%\n 1 2 3 60%\n 0 845 1,690 0 5,176 10,353 0 241 482 0 1,462 2,924\n\n 40%\n 20%\n\nFig. 1 | Single-cell profiling of the human uterus. a, Schematic illustration of the human uterus showing the different layers and the morphological changes\nseen throughout the menstrual cycle with respect to tissue sampling. b, UMAP projections of scRNA-seq data from a total of 15 individuals. c, UMAP\nrepresentations colored by menstrual phase. d, UMAP of subclustered immune populations. e, UMAP projections of snRNA-seq data from a total of four\nindividuals in the proliferative phase. f, Radial representation of the cosine distance similarity for single cells obtained from snRNA-seq to the centroids\nof cell types defined by scRNA-seq. g, Estimated amount of mRNA (color intensity) contributed by each cell population to each spot (color) shown over\nthe hematoxylin and eosin (H&E) image of the secretory endometrium (A30, 152811 slide). h, Dot plot showing log2-transformed expression of genes\nexpressed in fibroblast and stromal subsets. i, Estimated amount of mRNA (color intensity) contributed by each cell population to each spot (color) shown\nover the H&E image of proliferative (A30, 152810 slide) and secretory (A30, 152811 slide) endometrium. Art, artery; DC, dendritic cell; fibro, fibroblast;\nGland, glandular; ILC, innate lymphoid cell; Lymph, lymphoid; Lumen, lumenal; Mac, macrophage; PV, perivascular; T, T cell; uM, uterine macrophage; uNK,\nuterine natural killer cell; uSMC, uterine smooth muscle cell.\n\n1700 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\n\n a Differentiated epithelium b c\n SOX9\n Proliferative\n epithelium SOX9\n + Proliferative\n Lumenal\n Ð\n LGR5 +\n Secretory\n SOX9\n +\n LGR5\n Ciliated Pre-ciliated\n Endometrium\n\n\n Lumenal Lumenal 2\n Ciliated\n Lumenal 1\n epithelium\n Glandular\n\n\n Glandular Ciliated\n Glandular LGR5\n\n\n UMAP2\n UMAP2\n Myometrium\n\n\n Glandular\n secretory\n UMAP1\n UMAP1\n\n d f Proliferative phase\n DAPI\n Proliferative phase Secretory phase WNT7A\n LGR5\n + Ð\n etory\n EPCAM\n +\n prolif +\n LGR5 OX9+LGR5 re-ciliated iliated landular ar secr al\n SOX9 SOX9 S P C G Glandul Lumen\n\n SOX9 prolif\n + +\n SOX9 LGR5\n + Ð\n SOX9 LGR5\n Pre-ciliated\n Ciliated\n +\n Ciliated LGR5\n Glandular\n Glandular secretory\n Lumenal 2\n Lumenal 1\n SOX9\n PGR\n ESR1\n MMP7\n CPM\n FHL2\n MKI67\n HMGB2\n PLAU\n IL32\n TNF\n WNT7A\n KRT17\n KRT5\n\n IHH\n EMID1\n PPARG\n MUC12\n CDC20B\n CCNO\n HES6\n FOXJ1\n PIFO\n TP73\n HEY1\n ABCG1\n SCGB2A2\n C2CD4A\n SLC18A2\n PAEP\n CXCL14\n SPP1\n GPX3\n DPP4\n PTGS1\n CLDN22\n PAX2\n IL6\n VTCN1\n SLC26A7\n MSLN\n LGR5\n\n\n Mean expression Fraction of cells\n in group in group (%)\n 250 µm 25 µm\n 0 5 20 40 60 80 100\n\n\n e g\n Proliferative + Ð Secretory\n SOX9 LGR5 Lumenal 1\n\n\n 0 3,090 6,181 0 120 240\n +\n SOX9 proliferative\n Glandular secretory\n\n 0 3,256 6,512\n 0 802 1,605\n + +\n SOX9 LGR5\n\n\n 0 555 1,110\n\n\n 1,000 µm 1,000 µm\n\n\n h KRT5 SCGB2A2\n Proliferative Secretory Proliferative Secretory\n\n\n 250 µm 250 µm 250 µm 250 µm\n COX-1 (PTGS1)\n Proliferative Secretory\n\n\n 250 µm 250 µm\n\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1701\n\nArticles NaTurE GEnETICS\n\nFig. 2 | Temporal and spatial dynamics of endometrial epithelial cells. a, Schematic illustration of epithelial subsets in the differentiated endometrium\nhighlighting the anatomical location of the glandular and lumenal epithelia. b, UMAP of subclustered and subsampled epithelial populations. c, UMAP\nof subclustered and subsampled epithelial populations colored by their menstrual phase. d, Dot plot showing the log2-transformed expression of genes\ncharacteristic of each epithelial subset. e, Number of mRNA molecules per spot (color intensity) confidently assigned to each epithelial subpopulation\n(color) in the proliferative phase (A13, 152810 slide). f, High-resolution large-area imaging of a section of proliferative endometrium, stained with in situ\nhybridization (smFISH) for WNT7A and LGR5 (SOX9+LGR5+ epithelial markers). White arrowheads indicate lumenal and glandular regions shown at higher\nmagnification (right). Representative image of four proliferative endometrial samples from four different donors. Scale bars: left, 250 μm; other, 25 μm.\ng, Number of mRNA molecules per spot (color intensity) confidently assigned to each epithelial subpopulation (color) in the early-proliferative phase\n(A30, 152807 slide). h, Validation of KRT5, COX1 (marker of lumenal cells) and SCGB2A2 (marker of glandular population) with IHC in endometrial tissue\n(proliferative and secretory phases). Nuclei are counterstained with hematoxylin. Scale bars, 250 μm. Representative images of three proliferative and\nthree secretory endometrial samples from six different donors.\n\n\n After ovulation, secretion of progesterone induces the differen- We then correlated the clinical stages of endometrial adenocarcitiation of SOX9+ cells into specialized secretory cells found at the nomas with our cell signals. The more advanced stages of endomesurface and in glands (Extended Data Fig. 5d). To date, it has not trial adenocarcinomas (stages III and IV) have a greater SOX9+LGR5+\nbeen possible to distinguish between differentiated lumenal and signal (Wilcoxon test, stages I + II against stages III + IV, P value\nglandular subsets using specific transcriptomic signatures and 7.54 × 10−6) (Fig. 3b and Supplementary Table 3). We also linked the\nmarkers. We can now identify these subsets in our scRNA-seq data, SOX9+LGR5+ signals to the four molecular subtypes of endometrial\nconfirmed by integration with spatial transcriptomic data (Fig. 2g cancer defined by TCGA30. The SOX9+LGR5+ signature is stronger\nand Extended Data Fig. 4d,e) and revealing markers that are vali- in tumors characterized by high copy number (copy-number-high)\ndated at the protein level (Fig. 2h). There is enriched expression of alterations (Wilcoxon text, P value 6.72 × 10−13), typical of serous\nboth COX1 (encoded by PTGS1) and KRT5 in the lumenal epithe- endometrial adenocarcinomas and linked with a worse prognosis\nlium and SCGB2A2 in the glandular epithelium. (Supplementary Table 3). Indeed, all the copy-number-high tumors\n considered in our analysis (31 serous and 7 serous-like endome-\nSOX9+ epithelial cells in endometrial disorders. Disorders in trioid adenocarcinomas) were classified as SOX9+LGR5+. In conendometrial function have a profound impact on women’s health trast, copy-number-low tumors have a lower SOX9+LGR5+ signal\nand reproductive outcomes. There has been limited progress in (Wilcoxon text, P value 5.91 × 10−6) (Supplementary Table 3).\nthe study of these disorders over the past decade, partly due to the We then explored the expression of specific epithelial markers in\nchallenges in analyzing this highly dynamic and complex tissue. To microarray expression data available from peritoneal biopsies from\nidentify the cells involved in these disorders, we looked for tran- donors with endometriosis31 (Supplementary Table 3). As expected,\nscriptomic signatures in bulk RNA data from endometrial cancers endometriotic peritoneal lesions upregulate markers characterisand endometriotic lesions. tic of proliferative endometrium (SOX9+ and preciliated markers)\n We first deconvoluted the transcriptomes from bulk RNA sequenc- compared with normal peritoneum (Fig. 3c). In particular, peritoing data from serous and endometrioid endometrial adenocarcinomas neal lesions upregulate markers specific for the SOX9+LGR5+ subavailable in The Cancer Genome Atlas (TCGA), using our single-cell set (such as WNT7A and KRT17) with expression levels similar to\natlas as a reference. Deconvolution reveals that the signature of the those in proliferative endometrium (Fig. 3c). In contrast, markers of\nSOX9+ epithelial population is dominant in tumors (Fig. 3a). Based secretory epithelial cells, PAEP and SCGB2A2, or ciliated cells, PIFO\non expression signals in epithelial cells, endometrial adenocarcinomas and TP73, are expressed at similar levels as in normal peritoneum\nresolve into three patterns. The first, characterized by SOX9+LGR5+, (Extended Data Fig. 6b).\noccurs in 63% of serous and 24% of endometrioid adenocarcinomas. In summary, our analysis suggests that dysfunctional epithelium\nThe second, SOX9+LGR5−, is found in 33% of endometrioid adeno- is a major driver of endometrial disease. By defining the transcripcarcinomas but is absent from serous adenocarcinomas. The third tomes of our two SOX9 populations, we can show the specific cell\npattern, with expression of differentiated ciliated or glandular signals, signals that dominate in endometrial carcinomas and endometriosis.\nis present in <10% of endometrial carcinomas. In line with these\nresults, markers characteristic of the SOX9+LGR5+ subset (for exam- Effect of microenvironments on epithelial identity. Having\nple, WNT7A, MSLN, KRT17, PTGS1 and VTCN1) are all upregulated defined these distinct epithelial cell states and their potential role in\nin tumors with a SOX9+LGR5+ transcriptomic signature compared to pathology, we focused next on the transcription factors (TFs) that\ntumors with a SOX9+LGR5− signature (Extended Data Fig. 6a). regulate epithelial differentiation throughout the menstrual cycle\n\n\nFig. 3 | Epithelial signatures in endometrial disorders. a, Heatmaps showing the relative contribution of single-cell-derived signals from healthy\nendometrium (rows) in explaining the bulk transcriptomes of 430 endometrioid and 122 serous endometrial adenocarcinomas from TCGA (columns).\nb, Analysis of the 313 endometrial adenocarcinoma TCGA samples that exhibit SOX9+LGR5+ or SOX9+LGR5− exposure above the intercept value. A\nKruskal–Wallis test was performed on cohorts of samples regrouped in association with cancer stages from I to IV (n = 201, 26, 72 and 14, respectively).\nThe SOX9+LGR5+ exposure depends on the stage of the tumor. Wilcoxon tests show that the increased value associated with later stages is significant for\neach stage partition (horizontal lines denote binary partitions: n = 201 versus 112, n = 227 versus 86, n = 299 versus 14). Black dots are individual exposure\nvalues. Boxplots represent quartiles while whiskers extend up to 1.5 times interquartile range (IQR) beyond each box to encapsulate extrema. c, Boxplots\nshowing normalized expression levels of epithelial marker genes in endometrium and peritoneum from control donors and patients with endometriosis\nfrom GSE141549. Expression in red, white or black peritoneal lesions is compared with endometrium and normal peritoneum by two-sided Wilcoxon test\n(not significant (NS): P > 0.05). Boxplots represent quartiles and whiskers extend up to 1.5 times IQR beyond each box to encapsulate extrema. For the\nproliferative and secretory comparisons, the number of independent biological samples was, respectively: control endometrium (n = 17 and n = 25), control\nperitoneum (n = 4 and n = 8), peritoneum red lesions (n = 2 and n = 7), peritoneum white lesions (n = 5 and n = 4) and peritoneum black lesions (n = 6 and\nn = 5). E, endometrium; E Pat, endometrium (patient); Expr, expression; P, peritoneum; P lesion B, peritoneal lesion black; P lesion R, peritoneal lesion red;\nP lesion W, peritoneal lesion white; P Pat, nonlesional control peritoneum (patient).\n\n1702 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\n\n a Endometrial adenocarcinoma (TCGA)\n Exposures\n 0.6 b\n 0.4 SOX9 +\n +\n 0.2 Kruskal test (LGR5 )\n –7\n LGR5 +–\n 0 P : 2.8 × 10 LGR5\n PV STEAP4 pR2\n Epithelial lumenal 2 1\n –8\n Lymphoid 0.8 P : 3.1 × 10\n Epithelial ciliated 0.6 –6\n Endothelial artery 0.4 P : 7.54 × 10\n Epithelial glandular\n 0.2 P : 0.00205\n Endothelial vein\n PV MYH11 0 0.6\n log10(fitCount)\n Fibroblast dS\n 8\n Epithelial gland_secretory\n + + 7.5 0.5\n Epithelial SOX9 LGR5\n Epithelial ciliated LGR5 7\n\n\n Exposure value\n Myeloid 6.5 0.4\n uSMC 6\n eS log10(obsCount)\n Epithelial SOX9 LGR5\n + – 8 0.3\n Epithelial pre-ciliated 7.5\n Fibroblast C7 7 0.2\n Epithelial lumenal 1 6.5\n Intercept 6\n pR2 log2(countRatio) 0.1\n log10(fitCount) 1\n log10(obsCount) 0.5 0\n log2(countRatio) 0\n −0.5\n Stage\n I\n Stage\n II III IV\n Tissue\n −1 Stage Stage\n Tissue\n Serous Cancer stage\n\n SOX9 LGR5\n + –\n SOX9 LGR5\n + +\n Ciliated\n 33% of endometrioid 24.4% of endometrioid 4.8% of endometrioid\n 63.1% of serous 1.6% of serous Endometrioid\n 0% of serous\n Glandular\n c 1.6% of endometrioid E Pat = Endometrium (patient)\n P Pat = Non-lesional control peritoneum (patient)\n P lesion R = Peritoneal lesion red\n Donors at proliferative stage Donors at secretory stage\n P lesion W = Peritoneal lesion white\n\n Markers for SOX9 + populations: P lesion B = Peritoneal lesion black\n 95\n\n 6\n\n\n PGR ESR1 MMP7 PGR ESR1 MMP7\n 9\n\n 2\n\n\n 9\n\n 6\n\n\n 8\n\n\n 8\n 00\n\n 01\n\n\n 01\n\n 03\n\n\n 01\n\n 01\n\n\n 04\n\n\n 04\n Lesions\n\n\n 16\n 0.\n\n 0.\n\n\n 0.\n\n 0.\n\n\n 14 17.5\n 0.\n\n 0.\n\n\n 0.\n\n\n 0.\n\n 00\n =\n\n =\n\n\n =\n\n =\n\n\n NS NS\n =\n\n =\n\n\n NS NS NS NS NS\n\n\n =\n\n\n =\n NS NS versus peritoneum\n 20\n P\n\n P\n\n\n P\n\n P\n\n\n 0.\n P\n\n P\n\n\n P\n\n\n P\n 32\n\n\n 12\n 03\n 33\n\n\n 4\n 00\n 2\n\n\n 3\n\n\n 2\n\n\n 8\n\n 2\n\n\n 08\n 01\n\n\n 01\n\n 00\n\n 01\n\n\n 04\n\n 01\n 00\n\n\n 8\n\n\n 7\n 0.\n\n\n 15.0 15.0 Lesions\n 03\n\n\n 03\n\n\n 03\n\n\n 00\n 12\n 0.\n\n\n 0.\n\n 0.\n\n 0.\n\n\n 0.\n\n 0.\n 0.\n\n =\n\n\n 0.\n\n\n 0.\n\n\n 0.\n\n\n 0.\n =\n\n\n =\n\n =\n\n =\n\n\n =\n\n =\n =\n\n\n NS\n P\n\n\n NS NS 15 versus endometrium\n P\n\n\n P\n\n P\n\n\n NS NS NS\n =\n\n\n =\n\n\n =\n\n\n =\n P\n\n\n P\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n 15\n Expr\n\n\n Expr\n\n\n Expr\n\n\n Expr\n 10\n 10 12.5 12.5\n\n 10 10\n 8 10.0 8 10.0\n R\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n W\n\n B\n\n\n t\n le at\n\n\n P nW\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n P PP\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n\n o\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n Markers for SOX9 +LGR5 + population:\n\n\n 62\n 95\n\n\n 16\n 9\n\n\n WNT7A KRT17 LGR5\n 16\n 4\n 6\n\n\n WNT7A KRT17 LGR5\n 6\n\n\n 8\n 6\n 01\n\n\n 00\n 01\n\n\n Lesions\n 01\n\n\n 04\n\n\n 00\n 01\n\n 00\n\n\n 00\n\n\n 00\n 0.\n\n\n 0.\n 0.\n\n\n 0.\n\n\n 0.\n\n\n 0.\n 0.\n\n 0.\n\n\n 0.\n\n\n 0.\n\n\n 12\n =\n\n\n NS NS versus peritoneum\n =\n =\n\n\n =\n\n\n NS\n =\n\n\n =\n NS\n =\n\n =\n\n\n =\n\n\n NS NS NS NS\n =\n\n\n 9\n P\n\n\n P\n P\n\n\n 9\n P\n\n\n P\n\n\n P\n P\n\n P\n\n\n P\n\n\n 12\n P\n 5\n 10 –\n\n\n 1\n 2\n\n\n 12 11\n 2\n\n\n 7\n\n\n 01\n 01\n\n\n 02\n\n\n ×\n 6\n\n\n Lesions\n 01\n\n\n 03\n\n\n 12\n 00\n\n 6\n\n\n 0.\n 0.\n\n\n 0.\n 0.\n\n\n 0.\n 5.\n 0.\n\n\n NS NS\n =\n =\n\n\n =\n\n\n NS NS NS NS NS NS versus endometrium\n =\n\n\n NS NS\n =\n =\n\n\n NS\n =\n\n\n P\n P\n\n\n P\n P\n\n\n P\n P\n P\n\n\n 8 10\n Expr\n\n\n 10 8\n Expr\n\n\n Expr\n\n\n Expr\n\n\n 10 10\n 9\n\n 8 7 8 8 7\n 8\n 7\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n le at\n\n R\n P nW\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n si t\n R\n P nW\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n le W\n\n B\n Pa\n\n Pa\n\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n P\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n P on\n\n\n on\n\n\n n\n\n\n on\n\n\n P on\n on\n\n\n on\n\n\n on\n\n\n on\n o\n E\n\n P\n\n\n E\n\n P\n\n\n o\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n o\n\n\n E\n\n P\n\n\n E\n\n P\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n Markers for SOX9 +LGR5 – population:\n 95\n 6\n\n\n IHH EMID1\n 8\n\n\n PPARG\n 2\n 6\n\n\n IHH EMID1 PPARG\n 01\n\n 03\n\n\n 03\n\n 00\n 01\n\n\n Lesions\n 0.\n\n 0.\n\n\n 0.\n\n 0.\n 0.\n\n\n 9.0\n =\n\n\n 14\n =\n\n\n =\n\n =\n\n\n NS NS\n =\n\n\n NS NS NS NS NS NS versus peritoneum\n P\n\n\n NS NS NS\n P\n\n\n 14 NS NS\n P\n\n P\n P\n\n\n 10\n 3\n 14\n\n\n 05\n\n\n 3\n\n\n 13\n 2\n 2\n\n\n 04\n 01\n\n\n 03\n\n\n 5\n 02\n 01\n\n 00\n\n\n 00\n\n\n 8.5 Lesions\n 01\n\n 03\n\n\n 12\n 0.\n\n\n 12\n 0.\n\n\n 0.\n 0.\n 0.\n\n 0.\n\n\n 0.\n\n\n 0.\n\n 0.\n\n\n 12\n =\n\n\n NS\n =\n\n\n =\n\n\n NS NS\n =\n\n\n NS NS\n =\n\n =\n\n\n =\n\n\n NS NS NS\n =\n\n =\n\n\n NS\n P\n\n\n versus endometrium\n P\n\n\n P\n P\n P\n\n P\n\n\n P\n\n\n P\n\n P\n\n\n 9\n Expr\n\n\n Expr\n\n\n Expr\n\n\n Expr\n\n\n 11 8.0\n 10 10 10\n\n 7.5 8\n 9\n 8 8\n 8\n 7 7.0 7\n le W\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n si t\n le n R\n\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n o\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n Markers for pre-ciliated population:\n 95\n\n\n MUC12 CCNO HES6 MUC12 CCNO HES6\n 6\n\n\n 6\n\n\n 6\n\n\n 03\n 01\n\n 00\n\n\n 01\n\n\n 01\n\n\n 0.\n\n\n Lesions\n 0.\n\n 0.\n\n\n 0.\n\n\n 0.\n\n\n 8.0\n =\n\n\n 8.5 NS\n =\n\n =\n\n\n 12\n =\n\n\n =\n\n\n NS NS NS NS NS NS NS NS NS\n P\n\n\n NS NS NS\n P\n\n P\n\n\n P\n\n\n P\n\n\n versus peritoneum\n 12\n 10\n 9\n\n\n 2\n 4\n\n\n 01\n 00\n 2\n\n 9\n\n\n 04\n 7\n\n\n 6\n\n\n 2\n\n 2\n\n 02\n\n\n 01\n\n 03\n 04\n\n\n 01\n\n\n 01\n\n 00\n\n\n 0.\n\n\n 9\n 0.\n\n\n 0.\n 0.\n\n\n 8.0 11\n 0.\n\n 0.\n 0.\n\n\n 0.\n\n\n 0.\n\n 0.\n\n\n =\n\n\n NS NS NS NS NS Lesions\n =\n\n\n =\n\n\n NS\n =\n\n\n NS NS\n =\n\n =\n =\n\n\n =\n\n\n =\n\n =\n\n\n 11 7.5\n P\n P\n\n\n P\n P\n\n\n P\n\n P\n P\n\n\n P\n\n\n P\n\n P\n\n\n 9 versus endometrium\n Expr\n\n\n Expr\n\n\n Expr\n\n\n 7.5 10 10\n 8\n 8 7.0\n 7.0 9 9\n 7\n 7 8 6.5\n 6.5 8\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n\n\n t\n\n t\n\n R\n\n W\n\n B\n\n\n t\n\n t\n R\n\n W\n\n B\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n\n\n Pa\n\n Pa\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n\n\n on\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n\n\n E\n\n P\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n\n\n si\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n\n\n le\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\n P\n\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1703\n\nArticles NaTurE GEnETICS\n\na b\n 1,000 µm\n Ciliary TFs log fold-change\n\n * * Preciliated\n 4\n * * Ciliated\n Glandular\n 2\n Glandular_secretory\n Lumenal_1\n Lumenal_2 0\n FOXJ1\n RFX2\n HES6\n MYB\n RFX3\n TCF7\n TP73\n HOXA3\n HOXC4\n\n\n −2\n Clusters:\n −4 Lumenal Functional Basal\n Secretory TFs\n c Microenvironment\n Preciliated log fold-change\n 1 Lumenal\n Ciliated\n Glandular Gland\n 0.5\n * * Glandular_secretory Basal\n 0\n\n\n PTGS1\n LGR5\n TPPP3\n FOXJ1\n KLF6\n SCGB2A1\n PAEP\n N OTCH2\n CLU\n S OX9\n STC1\n CD74\n MUC5B\n * * Lumenal_1\n 0\n Lumenal_2\n −1\n CSRNP1\n HIF1A\n KMT2A\n FOSL2\n FOXO1\n HEY1\n HNF1B\n KLF4\n HES4\n PPARG\n\n\n −0.5\n\n −2 −1\n WNT activatory;\n WNT activatory; * Active TF WNT inhibitory;\n WNT inhibitory; NOTCH activatory\n NOTCH activatory\n\n\nd smFISH signal for NOTCH2 in full-thickness endometrium e smFISH quantification in full-thickness endometrium\n NOTCH2 WNT7A\n Max\n Increasing distance from lumen\n Spot intensity per gland area\n\n\n Spot intensity per gland area\n smFISH signal\n\n\n 25 50\n Secretory phase\n Replicate 1\n\n\n 20\n 25\n\n Min 15\n\n 0\n 0 2,000 4,000 0 2,000 4,000\n Distance from lumen (µm) Distance from lumen (µm)\n 60\n Spot intensity per gland area\n\n\n Spot intensity per gland area\n\n\n 18\n Secretory phase\n\n\n 40\n Replicate 2\n\n\n 16\n\n\n 14\n 20\n 12\n\n\n 0 2,000 4,000 0 2,000 4,000\n Distance from lumen (µm) Distance from lumen (µm)\n Spot intensity per gland area\n\n\n Spot intensity per gland area\n\n\n 30\n Secretory phase\n\n\n 15\n Replicate 3\n\n\n 20\n\n\n 10\n 10\n\n\n 1,000 µm\n 0 2,000 4,000 0 2,000 4,000\n Distance from lumen (µm) Distance from lumen (µm)\n\n\nby analyzing expression of TFs and their consensus target genes32 the glandular subsets show high expression for TFs induced by\n(Fig. 4a and Supplementary Table 4). There is high activity of WNT WNT inhibition (for example, CSRNP1 and FOXO1) and NOTCH\ntargets (for example, FOXJ1) in the ciliated epithelium. In contrast, activation (for example, HES1 and HEY1). This suggests different\n\n1704 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\nFig. 4 | Cell signaling in glandular and lumenal epithelium. a, Heatmaps showing TFs differentially expressed in ciliated (top) and secretory (bottom)\nepithelial lineages. Color is proportional to log-transformed fold change; asterisks highlight TFs whose targets are also differentially expressed (that is,\ndifferentially activated TFs). b, Unbiased clustering of epithelial subsets using Visium data. Spot colors represent cluster assignment based on Louvain\nclustering of spots assigned to epithelial subsets. Spots assigned to one of the clusters (represented in light gray in the figure) were excluded from the\nanalysis due to the low percentage of epithelial cells in the spot after visual inspection. c, Heatmap showing log-transformed fold change of differentially\nexpressed genes between the three main clusters defining the lumenal, functional and basal epithelial regions. d, High-resolution large-area imaging of\na representative section of secretory-phase endometrium, with pseudocolor intensity proportional to smFISH signal for NOTCH2. Representative image\nof three endometrial samples from three different donors. e, smFISH quantification in three full-thickness secretory-phase endometrial samples. Plots\nrepresent smFISH spot intensity in glands divided by gland area at increasing distances from the lumen. Approximate lumen range is marked in yellow.\n\n\nroles for NOTCH and WNT in shaping the identity and function of NOTCH interactions are mainly mediated by the epitheciliated versus secretory cells. lial compartment (Fig. 5c), with the NOTCH ligand JAG1 more\n To investigate the cell signals operating in the lumenal and glan- highly expressed in the lumen than in glands, as shown by smFISH\ndular microenvironments that could influence differentiation into (Extended Data Fig. 7b,c). As well as JAG1 being coexpressed with\nciliated and secretory lineages, we used spatial transcriptomics and HEY1, sparse JAG1high epithelial cells are often adjacent to JAG1low\nperformed clustering on the 10x Genomics Visium spots assigned to cells expressing HEY1 (Extended Data Fig. 7c). A similar lateral\nepithelial subsets. We resolve five clusters corresponding to cells in NOTCH inhibition model has been described in the gut34.\nthe lumenal (one cluster), functional (two clusters) and basal (two WNT ligands are expressed by both epithelial and stromal cells\nclusters) layers (Fig. 4b). In addition to cell-type-specific markers, (Fig. 5c); the latter express WNT agonists that can potentially bind\nsignatures of WNT and NOTCH signaling pathways are present in the cognate WNT receptors expressed by all epithelial subsets durdistinct endometrial regions (Fig. 4c and Supplementary Table 5). ing the proliferative phase (Fig. 5c). Focusing on genes that are\nGenes involved in the WNT pathway, FOXJ1 and LGR5, are highly differentially expressed following ovulation, glandular secretory\nexpressed at the lumenal surface while NOTCH2 is enriched in subsets show a dramatic decline in WNT receptor expression, potenglands in the functional layer. To validate expression of NOTCH2 tially limiting the activity of this pathway (Fig. 5c). They also show\nand WNT7A in these compartments, we stained uterine tissue with a decrease in the WNT target AXIN2 when compared with their\nsmFISH probes for both genes alongside EPCAM using immunohis- lumenal counterparts (Extended Data Fig. 7d). In addition, decidutochemistry (IHC) (Fig. 4d,e). Lumenal and glandular epithelial cells alized stromal cells express significantly higher levels of DKK1, a\nwere classified automatically based on EPCAM expression, and the potent inhibitor of the WNT pathway, than their nondecidualized\ndistance of the signal from the lumen was then measured (Methods). counterparts. Expression of DKK1 surrounding the glands of the\nOur results show that NOTCH2 expression increases in glands mov- secretory endothelium is also found in spatial transcriptomics (Fig.\ning away from the lumen while WNT7A expression is higher in the 5d). Overall, these findings strongly suggest that WNT signaling is\nlumenal epithelium compared with glands (Fig. 4e). By contrast, the inhibited in the secretory cell lineages, meaning that NOTCH signoncanonical WNT molecule WNT5A was mainly expressed in stro- naling will then dominate (Fig. 5e).\nmal cells surrounding the glands (Extended Data Fig. 7a). These findings suggest that canonical WNT is downregulated in the glandular Response of endometrial organoids to ovarian hormones. To\nmicroenvironment where noncanonical WNT pathways dominate. test our predictions on the potential roles of WNT and NOTCH\n To investigate how surrounding cells may shape signaling in the signaling pathways on endometrial epithelium in vitro, we first\nsurface and glandular compartments, we developed CellPhoneDB profiled endometrial organoids at a single-cell level to benchmark\nv.3.0, an updated version of our cell–cell communication pipeline this model system against our in vivo data. We derived organthat takes into account spatial cellular colocalization when map- oids10 from three different donors and primed them as previously\nping ligand–receptor pairs33 (Methods and Fig. 5a). CellPhoneDB described with estrogen for 48 h, followed by stimulation with\nconsiders the multimeric composition of the majority of ligands progesterone, prolactin and cyclic AMP (cAMP) in the presence\nand receptors, which is highly relevant for the complex regulation of estrogen for 4 d (ref. 10) (Fig. 6a and Supplementary Tables 7\nof WNT signaling (Fig. 5b). We define three endometrial microen- and 8).\nvironments centered on epithelial cells based on the cellular coor- To identify epithelial cells in the organoids, we looked for markdinates provided by cell2location: (1) lumenal—preciliated, ciliated ers specific to the clusters. Before hormonal treatment, the majority\nand SOX9+LGR5+ epithelium (proliferative phase) and ciliated and of cells within the organoids are proliferative (expressing TOP2A,\nlumenal (secretory phase); (2) functional—SOX9+ proliferative epi- PCNA) and all express the estrogen receptor ESR1 (Fig. 6b–d and\nthelium, immune and eS (proliferative phase) and immune, glan- Extended Data Fig. 8a,b). Two additional populations emerge when\ndular and dS (secretory phase); and (3) basal—SOX9+LGR5− and the organoids are treated with estrogen: (1) an estrogen-induced popfibroblasts C7. We ran CellPhoneDB on each of the microenviron- ulation expressing the progesterone receptor (PGR), a target gene of\nments (Supplementary Table 6) and found significant epithelial– estrogen, and (2) a preciliated population sharing markers with the\nstromal interactions (log fold change > 0.02 and false discovery rate equivalent cluster defined in vivo. Upon further stimulation with\n(FDR) < 0.005). progesterone, markers of more advanced stages of differentiation\n\n\nFig. 5 | Interrogation by CellPhoneDB v.3.0 of ligands and receptors mediating epithelial differentiation. a, Adaptation of our cell–cell communication\ntool that considers spatial cellular dynamics and is available at https://github.com/Ventolab/CellphoneDB. b, Schematic illustration of receptors and\nligands involved in WNT and NOTCH signaling. c, Dot plots showing expression of CellPhoneDB v.3.0 relevant ligands in epithelial, stromal and fibroblast\npopulations with cognate receptors in epithelial subsets. Only significant interactions (fold change > 0.02 and FDR < 0.005) are represented. The\ncolor of the arrows corresponds to the pathways whose ligand–receptor partners are involved, as shown in b. d, Estimated proportions of DKK1 in the\nearly-proliferative phase (A30, 152807 slide). e, Schematic illustration of our proposed model for temporal and spatial distribution of epithelial and stromal\nsubsets across the menstrual cycle. The proliferative phase is dominated by a WNT environment that promotes regeneration. Compartmentalization of\nWNT and NOTCH signaling during the secretory phase promotes efficient differentiation toward the ciliated and secretory lineages.\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1705\n\nArticles NaTurE GEnETICS\n\nemerge in both secretory and ciliated populations. Markers of closely match their in vivo counterparts. IHC of endometrial organsecreted products (PAEP, DEFB1) and glands (SCGB2A2) are both oids confirmed the expression of glandular and ciliary markers after\nseen. Ciliated cells express typical markers (FOXJ1, TP73) and hormonal stimulation (Fig. 6e).\n\n a b d\n WNT activation\n WNT RSPO DKK1\n CellPhoneDB v.3 20\n 1,000 µm\n LRP5/6\n a- Differentially expressed FZD LGR4/5/6\n interacting ligand and 15\n WNT inhibition\n receptors (scRNA-seq) DKK1 WNT\n DKK1\n Multimeric SOSTDC1\n WIF1\n complexes\n E.g. WNT 10\n 1 b- Cells co-existing in a KREMEN LRP5/6 LRP5/6\n 0 microenvironment receptors\n –1\n Gene\n (Spatial transcriptomics) (FZD–LRP)\n expression NOTCH DLL JAG 5\n activation/inhibition\n\n High confidence cell–cell interactions NOTCH NOTCH\n 0\n c\n Ligands Receptors\n Proliferative WNT9A FZD8\n % of cells WNT7A FZD7\n stage WNT6 % of cells\n in group FZD6\n WNT5B FZD5 in group\n 0.25 WNT5A FZD3 0.2\n 0.50 WNT4 FZD2 0.4\n 0.75 WNT2B FZD10 0.6\n WNT2 FZD1\n WNT11 LRP6\n Mean RSPO3 Mean\n LRP5\n expression RSPO1 LGR5 expression\n DKK1 LGR4\n 5 SOSTDC1 1.5\n 4 KREMEN1\n NDP 1.0\n 3 DLL1\n NOTCH4\n 2 JAG2\n NOTCH3 0.5\n 1 JAG1\n NOTCH2\n NOTCH1\n Ciliated\n\n Pre-ciliated\n\n +\n\n\n SOX9 prolif\n\n –\n Fibroblast_C7\n Ciliated\n Pre-ciliated\n +\n\n\n SOX9 prolif\n eS\n Lymphoid\n –\n\n\n SOX9 LGR5\n SOX9 LGR5\n SOX9 LGR5\n SOX9 LGR5\n\n\n +\n +\n\n\n +\n +\n +\n +\n\n\n Lumenal Functional Basal Lumenal Functional Basal\n Ligands Receptors\n Secretory WNT7B FZD8\n % of cells WNT7A % of cells\n stage FZD6\n in group WNT5B FZD5 in group\n 0.2 WNT5A FZD3 0.2\n 0.4 WNT4\n FZD1 0.4\n 0.6 WNT2B\n LRP6\n 0.6\n 0.8 WNT2 Mean\n RSPO3 LRP5\n Mean RSPO1 LGR5 expression\n expression DKK1 LGR4 2.0\n NDP KREMEN1 1.5\n 3 DLL1 NOTCH3 1.0\n 2 JAG2 NOTCH2\n JAG1 0.5\n 1 NOTCH1\n Ciliated\n Lumenal_1\n Lumenal_2\n Glandular\n Gland_secretory\n dS\n Lymphoid\n\n\n Fibroblast_C7\n –\n SOX9 LGR5\n\n\n Ciliated\n\n Lumenal_1\n\n Lumenal_2\n\n Glandular\n\n Gland_secretory\n –\n SOX9 LGR5\n +\n\n\n +\n\n\n Lumenal Functional Basal Lumenal Functional Basal\n\n Epithelial\n e Menstrual phase Proliferative phase Secretory phase\n + –\n SOX9 LGR5 cell\n ovarian hormones\n Relative levels of\n\n\n SOX9 proliferative\n E2 + +\n P4 SOX9 LGR5 cell\n\n Lumen Glandular Pre-ciliated\n WNT NOTCH\n NOTCH WNT\n Ciliated\n\n Lumenal\n\n Glandular pre-secretory\n Endometrial cycle\n\n\n Glandular secretory\n Functional\n layer Non-decidualized\n endometrial stromal cells (eS)\n Basal layer Decidualized\n Myometrium endometrial stromal cells (dS)\n Fibroblast C7 (fibro C7)\n 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28\n Menstrual cycle (d)\n\n\n1706 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\n\n a b c Days 0 2 6\n No hormones\n NH Day0 NH Day2\n\n NH Day6\n Growth Hormonal\n stimulation NH Ciliated\n Proliferative\n Seeding\n Ciliated\n\n\n UMAP2\n 10,000 cells per well d0 d2 d6 Days\n 9d\n ExM ExM+E2 ExM+E2+P4+cAMP+PRL Medium Estrogen KRT17+\n induced Pre-ciliated UMAP1\n\n * * * Collection Secretory Secretory Medium NH E2 E2+P4\n cycling\n\n\n UMAP2\n Secretory\n UMAP1\n\n\n d\n\n\n UMAP2\n NH Day0\n NK Proliferative\n NH Day2\n NH Day6 UMAP1\n Estrogen induced\n Pre-ciliated\n Ciliated\n Secretory\n Secretory proliferative Mean expression Fraction of cells\n +\n KRT17 in group in group (%)\n\n\n SERPINA5\n SCGB1D2\n\n\n TFCP2L1\n EPB41L2\n\n\n RANGRF\n\n\n CDC20B\n FAM69B\n ERICH5\n HMGB2\n\n\n WNT7A\n MUC12\n\n\n PTGS1\n PTGS2\n PRR15\n\n\n DEFB1\n PLCB1\n\n\n FOXJ1\n\n\n CCL20\n\n\n CCL20\n\n\n KRT17\n EMID1\n\n\n S100P\n CCNO\n MKI67\n\n\n MMP7\n SOX9\n\n\n PAEP\n\n\n GPX3\n ESR1\n\n\n HES6\n\n\n LGR5\n\n\n PLAU\n\n\n LGR5\n STC1\n FHL2\n\n\n TP73\n PIFO\n CPM\n PGR\n\n\n IL32\n TNF\n 2 4 20 40 60 80 100\n\n\n e Control Differentiated f\n SCGB2A2 Projected epithelial subsets\n\n Estrogen Pre-ciliated\n induced\n In vivo subsets:\n Ciliated\n Lumenal\n Glandular\n Pre-ciliated\n UMAP2\n\n\n Secretory\n Ciliated\n Ciliated LGR5 +\n HEY1 SOX9 +LGR5 Ð\n SOX9 +LGR5 +\n\n\n g UMAP1\n TFs ciliary log fold-change\n Estrogen_Induced 4\n FOXJ1 Secretory 2\n Secretory_Proliferative\n 0\n ** Preciliated\n ** Ciliated −2\n FOXJ1\n RFX2\n HES6\n MYB\n RFX3\n TCF7\n TP73\n HOXA3\n HOXC4\n\n\n −4\n *Active TF −6\n TFs secretory\n log fold-change\n Estrogen_Induced\n *** * * Secretory 1\n * * * * Secretory_Proliferative\n Preciliated\n 0\n Ciliated\n −1\n CSRNP1\n HIF1A\n KMT2A\n FOSL2\n FOXO1\n HEY1\n HNF1B\n KLF4\n HES4\n SMAD3\n FOXO3\n NFKB1\n HES1\n\n\n *Active TF −2\n\n\n h Pseudotime Ciliated probability Secretory probability\n 1.0\n Pre-ciliated Ciliated\n Estrogen induced\n 0.8 0.8\n 0.8\n\n 0.6 0.6\n UMAP2\n\n\n UMAP2\n\n\n UMAP2\n\n\n UMAP2\n\n\n 0.6\n Ciliated Secretory\n Secretory 0.4 0.4 0.4\n\n 0.2 0.2 0.2\n\n 0 0\n UMAP1 UMAP1 UMAP1 UMAP1\n\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1707\n\nArticles NaTurE GEnETICS\n\nFig. 6 | In vitro responses of endometrial organoids to ovarian hormones are similar to in vivo epithelial changes. a, Experimental timeline of endometrial\norganoid cultures. Organoids were derived in ExM and then subjected to hormonal stimulation with estrogen (E2) followed by estrogen + progesterone\n(P4) + cAMP and prolactin (PRL). The time points at which organoids were collected for scRNA-seq are marked with an asterisk. b, UMAP projections\nof scRNA-seq data identify major cellular populations. c, UMAP representations colored by days after hormonal stimulation (top) or by treatments\n(bottom). d, Dot plot showing log2-transformed expression of selected genes that distinguish the main cell populations. e, IHC to validate markers of\nthe secretory population, SCGB2A2 and HEY1, and combined staining for FOXJ1 and acetylated α-tubulin in control (undifferentiated) and differentiated\n(hormonally stimulated) organoids. Black arrowheads indicate ciliated cells with FOXJ1-positive nuclei. Nuclei are counterstained with hematoxylin. Scale\nbars: 250 μm (red), 200 μm (black). Representative images of three endometrial organoids from three different donors. f, Predicted epithelial subsets of\nendometrial organoids using a logistic classifier. g, Heatmaps showing TFs differentially expressed in ciliated and secretory lineages. Color is proportional\nto log-transformed fold change, with asterisks highlighting TFs whose targets are also differentially expressed (that is, differentially activated TFs). h, Cells\nable to respond to progesterone derived from a clonal organoid culture (E001 individual) (Methods) are colored from left to right: (1) cluster labels as in\nExtended Data Fig. 8e; (2) Palantir pseudotime; (3) probability of cells to progress toward the ciliary lineage; and (4) probability that the cell differentiates\ntoward the secretory lineage. NH, no hormone.\n\n\n We next assessed how closely the hormonal responses of the reconstruct epithelial differentiation in response to hormones (Fig.\norganoids that generate glandular and ciliated cells relate to their 6h and Extended Data Fig. 8g). A subset of cells emerging from\nin vivo counterparts. To focus on the hormonal responses to estrogen the estrogen-induced population differentiate into preciliated cells\nand progesterone, we performed a quantitative assessment of organ- in response to estrogen and, following additional progesterone,\noids exposed to estrogen and progesterone while maintaining them into ciliated cells. The secretory lineage also emerges from the\nin their expansion medium (ExM)10. Next, we projected the epithelial estrogen-induced population. Thus, there is a common progenitor\nin vivo reference data onto the hormone-treated in vitro epithelial for both lineages.\nsubsets. Assignments were made based on logistic regression predictions. In the absence of progesterone, the SOX9+ populations are the WNT and NOTCH inhibition mediates epithelial differentiabest match for estrogen-induced cells while preciliated organoid cells tion. To test the roles of the WNT and NOTCH pathways in ciliated\nalign with their preciliated in vivo counterparts (Fig. 6f, Extended and secretory differentiation, we cultured organoids in the presence\nData Fig. 8c and Supplementary Table 9). In response to hormones, of inhibitors of either NOTCH (DBZ or DAPT) or WNT (IWP-2\na large fraction (over a quarter of secretory cells) correspond to glan- or XAV939). We used functional, histological and single-cell trandular epithelium, and all ciliated cells match perfectly with their scriptomic assays to assess outcomes (Fig. 7a). Organoid viability\nin vivo counterparts, indicating that organoids respond similarly to is high under all conditions (Extended Data Fig. 9a). scRNA-seq\nhormones as in vivo (Fig. 6f and Supplementary Table 9). analysis reveals a higher proportion of preciliated and ciliated\n To determine whether the pathways driving hormonally induced cells and a lower proportion of secretory cells in the presence of\ndifferentiation toward the ciliated and secretory lineages are similar DBZ (NOTCH inhibitor) (Fig. 7b–d, Extended Data Fig. 9b,c and\nin vitro and in vivo, we looked at the differential expression and Supplementary Table 11). This finding was validated by IHC and\nactivity of lineage-specific TFs (Fig. 6g and Supplementary Table quantitative PCR with reverse transcription (RT–qPCR) using two\n10). We calculated differentially expressed or active TFs in the hor- NOTCH inhibitors (DBZ and DAPT) (Fig. 7e and Extended Data\nmonal subsets in vivo and in vitro. WNT-activated TFs (FOXJ1) are Fig. 9d). Ciliated cells are virtually absent when WNT is inhibited\npresent in the ciliated lineage while WNT-inhibitory TFs (CSRNP1, (presence of XAV939), highlighting the strong dependence on this\nFOXO1) are in the secretory lineage. NOTCH-induced TFs, HEY1 pathway for ciliary commitment, while the proportion of secreand HES1, are activated in the secretory lineage. These results indi- tory cells is increased under these conditions (Fig. 7b–d, Extended\ncate that ovarian hormones activate similar pathways both in vivo Data Fig. 9b,c and Supplementary Table 11). The drive toward the\nand in vitro. secretory lineage under WNT-inhibitory conditions (IWP-2 and\n These results mean that it is possible to reconstruct pseudotime XAV939) was further validated by RT–qPCR and IHC (Fig. 7e and\nand recapitulate cell fate decisions of epithelial cells in response to Extended Data Fig. 9d). These results demonstrate the fine balance\nhormones using endometrial organoids. We performed scRNA-seq between NOTCH and WNT signaling to regulate commitment to\non two clonal organoids from the same individual (Extended Data endometrial secretory or ciliary lineages.\nFig. 8d). Both clones showed similar behavior and were integrated Hormonal stimulation in the presence of WNT and NOTCH\nunder the same manifold (Extended Data Fig. 8e,f). Annotation inhibitors modified the secretory cell transcriptome (Fig. 7b). To\nof clusters was performed based on known markers, and then quantify the similarity of the secretory populations that emerged\nclusters expressing the progesterone receptor were selected to in the presence of inhibitors with their in vivo counterparts, we\n\n\nFig. 7 | WNT and NOTCH signatures dictate endometrial epithelial differentiation. a, Experimental timeline of endometrial organoid cultures. Organoids\nwere treated with inhibitors to either NOTCH (DBZ or DAPT) or WNT (IWP-2 or XAV939) upon initiation of hormonal stimulation. R-spondin-1 (RSPO-\n1) was omitted from ExM in the presence of WNT inhibitors. Collection time points for scRNA-seq are highlighted with asterisks. b, UMAP plots for\nscRNA-seq samples after either WNT or NOTCH inhibition. c, UMAP representations colored by inhibitor treatments (top) or hormonal stimulation\n(bottom). d, Bar plots showing enrichment of cells in ciliated and secretory clusters after NOTCH or WNT inhibition compared with untreated controls,\nanalyzed with unpaired z-tests. e, IHC for acetylated α-tubulin (ciliary marker) and glycodelin (PAEP). Scale bars, 200 μm. Representative images of\nendometrial organoids derived from three different patients. Blue arrowheads indicate ciliated cells, orange arrowheads indicate secretory cells and\ngreen arrowheads indicate glandular secretions. f, Dot plot showing the log2-transformed expression of genes characteristic of endometrial secretions in\nepithelial subsets. g, Radial representation of the cell type probabilities predicted by a logistic model trained on epithelial cells in vivo. The linear projection\nshows cells in each corner whenever a cell is predicted to belong to a given class with a probability of 1. h, Volcano plots representing differentially\nexpressed genes within the secretory lineage in two comparisons: (1) cells cultured with and without WNT inhibitor; progesterone is present in the media;\nand (2) cells cultured with and without hormones; WNT inhibitor is present in the media. TFs that are significant in the in vivo dataset are highlighted.\ni, Heatmap showing differential activities of TFs significant in the in vivo analysis. Ctrl, control; NOTCHi, NOTCH inhibitor; WNTi, WNT inhibitor.\n\n1708 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\nmeasured the expression levels of genes encoding secretory prod- We validated the increase of one secretory product, PAEP, under\nucts. Expression levels for PAEP and DEFB1 are higher when WNT WNT-inhibitory conditions by ELISA (Extended Data Fig. 9e).\nis inhibited and downregulated with NOTCH inhibition (Fig. 7f). Although PAEP expression levels increase slightly in the presence\n a d 100%\n Pre-ciliated\n Hormonal stimulation P = 0.0416\n Growth Ciliated\n NOTCH or WNT inhibition\n 80%\n P = 0.0147\n\n Seeding\n 10,000 cells per well 60%\n\n\n Efficiency\n d0 d2 d6 Days\n 9d\n ExM+E2 ExM+E2+P4+cAMP+PRL Medium 40%\n ExM\n DBZ/DAPT or IWP-2/XAV-939 Inhibitors\n Collection 20%\n * * * P = 0.0146 P = 0.0049\n b c Inhibitors Ctrl NOTCHi WNTi\n 0%\n Estrogen Ciliated\n\n\n Ctrl\n\n\n NOTCHi\n\n\n WNTi\n\n\n Ctrl\n\n\n NOTCHi\n\n\n WNTi\n No hormones induced\n Pre-ciliated Day 2 Day 6\n\n P = 0.006\n NH Day0 Estrogen 100%\n Secretory\n induced Ciliated\n 80% P = 0.04\n\n UMAP2\n NH Day2\n NH Day2 &\n WNTi\n Day6 Secretory UMAP1 60%\n\n\n Efficiency\n NH NOTCHi Medium NH E2 E2+P4\n Day6 Secretory 40%\n\n\n Secretory 20%\n UMAP2\n\n\n NH Day6 WNTi\n WNTi Secretory 0%\n +\n KRT17\n UMAP2\n\n\n Ctrl\n\n\n NOTCHi\n\n\n WNTi\n UMAP1\n Day 6\n UMAP1\n\n\n Estrogen_induced_PGR+\n e f Secretory_NOTCHi\n Secretory_WNTi\n\n\n Secretory_Ctrl\n\n\n NH_d6_WNTi\n\n NH_d2_WNTi\n Inflammatory\n\n\n Pre-ciliated\n\n\n NH_d2_d6\n No inhibitors Ð Hormones No inhibitors Ð No hormones Ciliated\n\n\n NH_d6\n\n\n NH_d0\n Acetylated α-tubulin PAEP Acetylated α-tubulin PAEP\n Fraction of cells\n in group (%)\n PAEP\n DEFB1\n 20 40 60 80 100\n CCL20\n SPP1\n Mean expression\n STC1 in group\n\n\n 2 4\n\n NOTCH inhibitors Ð Hormones WNT inhibitors Ð Hormones g Projections of epithelial subsets\n Acetylated α-tubulin PAEP Acetylated α-tubulin PAEP + + Ð\n Ciliated LGR5 SOX9 LGR5 In vitro\n Estrogen-induced\n IWP-2\n DZB\n\n\n + +\n Ciliated SOX9 LGR5 Pre-ciliated\n Ciliated\n Secretory control\n Pre-ciliated Lumenal 1\n Secretory NOTCHi\n XAV939\n DTPA\n\n\n Secretory WNTi\n\n Glandular Lumenal 2 KRT17+\n secretory\n Glandular\n\n h Secretory lineage Ð WNTi−Hormones versus Ctrl−Hormones Secretory lineage Ð WNTi−Hormones versus WNTi−NH i\n 10.0\n 30 log fold-change\n HIF1A\n 7.5 E2+P4 effect\n FOXJ1 20 5\n WNTi effect\n 0\n FOXJ1\n HIF1A\n PPARG\n HNF1B\n\n\n HEY1\n 5.0\n −5\n RFX2 10 FOXO1\n −10\n HNF1B\n TP73\n −log10(FDR)\n −log10(FDR)\n\n\n 2.5\n\n\n HOXC4\n CSRNP1\n\n\n HIF1A\n Differentially expressed and active\n Differentially expressed\n 0 PPARG 0 HES6 Not differentially expressed\n −2 −1 0 1 2 3 −2 0 2 4 6 Relevant in vivo\n log2(WNTi/Ctrl) log2(E2+P4/NH)\n\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1709\n\nArticles NaTurE GEnETICS\n\nof WNT inhibitors even in the absence of hormones, although this signaling mechanisms in the lumenal and glandular endometrial\nis not significant (Fig. 7f). In addition, we built a logistic regression microenvironments, which revealed that NOTCH and WNT pathmodel training the data on the organoids stimulated with distinct ways control ciliated and secretory epithelial cell commitment.\nhormonal and inhibitory conditions. Computational projection of Using our single-cell transcriptomics data as a reference to\nthe in vitro dataset onto the in vivo dataset shows similar overlaps deconvolute bulk data, we show that endometrial carcinomas and\nof the secretory populations emerging from WNT-inhibitory con- endometriotic lesions have a less differentiated epithelial phenotype\nditions and controls with their in vivo counterparts (Fig. 7g and than normal endometrium. Endometrial adenocarcinomas have\nSupplementary Table 12). This shows that WNT inhibitors target a two main signatures, SOX9+LGR5+ and SOX9+LGR5−, indicating\nspecific gene module relevant for glandular secretions. that these distinct transcriptomic signatures reflect differences in\n We next dissected the regulatory programs in the secretory lin- pathogenesis and disease progression. SOX9+LGR5+ is the domieage by comparing expression and activity of TFs between popu- nant signature in serous endometrial and some endometrioid adelations emerging after treatment with and without hormones and nocarcinomas and is positively associated with the ‘Copy-Number\nWNT inhibition. The expression of NOTCH-regulated TFs (HEY1) high’ molecular subtype from TCGA, as well as the clinically more\nis only upregulated in the presence of WNT inhibitors when hor- aggressive stage III and IV adenocarcinomas. Our study is consismones are present. This probably explains why WNT inhibitors are tent with previous analyses showing that serous adenocarcinomas\nnot sufficient to induce the secretory lineage on their own (Fig. 7h,i share molecular features with a subset of endometrioid tumors30. We\nand Supplementary Table 13). In the presence of hormones, WNT also show an enrichment of markers from SOX9+LGR5+ epithelial\ninhibition represses TFs characteristic of the ciliated lineage (FOXJ1, cells in endometriotic lesions, in line with findings that organoids\nTP73, RFX2) (Fig. 7h,i and Supplementary Table 13). Switching off derived from higher stages (III–IV) of endometriosis have higher\nthese genes therefore drives secretory lineage differentiation. expression of SOX9 (ref. 35). These organoid models will allow inves-\n To summarize, we show that by inhibiting NOTCH and WNT tigation of the potential roles of these SOX9 populations in driving\npathways it is possible to influence cell fate decisions between cili- endometrial cancer, endometriosis and other disorders35.\nary and secretory differentiation. This effect depends on the pres- Endometrial organoids are a powerful model to study normal\nence of estrogen and progesterone, and we can dissect the dialog endometrial epithelium10,11,36. We have systematically benchmarked\nbetween signaling pathways and hormonal stimulation in endome- the cellular composition of organoids relative to our in vivo refertrial differentiation. ence map. Machine learning approaches, such as logistic regression\n scoring of expression profiles as well as correlation analysis, have\nDiscussion been previously used to compare in vitro datasets with their in vivo\nProfiling the uterus in space and time is essential to define the cell counterparts37,38. Using a logistic regression approach, we demonstates and signaling pathways of normal human endometrium. This strate that endometrial organoids recapitulate the in vivo response\nspatiotemporal reference, using samples from healthy women, will to hormones, with the ciliary lineage becoming fully differentiated\nimprove understanding of the molecular and cellular aberrations while the secretory lineage maintains progenitors in addition to\noccurring in common conditions including infertility, endometriosis differentiated secretory cells. This provides compelling evidence\nand endometrial carcinoma. The uterine lining in women of repro- for the validity of our model. The organoids continue to expand\nductive age is a challenging tissue to study due to difficulty in access- during exposure to ovarian hormones because they are cultured in\ning samples covering the dynamic changes occurring across all stages ExM that promotes proliferation. We also compared TFs operating\nof the menstrual cycle. Here, we have used single-cell expression in vivo and in vitro and showed that similar programs are induced.\nanalysis, spatial transcriptomics and high-resolution quantitative Informed by these findings, further optimization of the culture conmultiplex imaging to generate profiles of uterine cell states through- ditions to achieve more complete secretory differentiation is underout the cycle. We focused on epithelial populations as they are major way. Our computational kit for in vivo and in vitro comparisons\nplayers in endometrial function and pathology, as suggested by our will be of general utility for tissue engineering experiments using\ncomparison of gene signatures with bulk RNA data from endome- Human Cell Atlas data as a blueprint.\ntrial diseases. We use and develop computational tools to integrate Our extensive validation assessing the hormonal responses of\nand analyze scRNA-seq and spatial data and investigate the molecu- the endometrial organoids means that we could use them to test\nlar mechanisms driving epithelial differentiation in the glandular the effects of NOTCH and WNT signaling on epithelial cell fate10.\nand lumenal microenvironments. We utilize our reference atlas to Inhibition of WNT signaling, which mimics the low-WNT microbenchmark endometrial organoids and engineer lineage-specific environment in differentiated glands, inhibits ciliary commitment\norganoids informed by signaling factors predicted by our in vitro– and induces secretory cells. In the presence of hormones, these cells\nin vivo comparisons. Our work shows the potential for using human produce more secretions, probably through stronger silencing of cilicell atlases as blueprints for tissue engineering experiments. ary genes. WNT inhibition alone does not result in secretory differ-\n There are two advances from our spatiotemporal uterine cell entiation, as the NOTCH pathway is not induced without hormonal\nreference atlas. First, we have profiled uterine cells from trans- stimulation. These results reinforce previous findings suggesting\nplant donors, allowing us to include the endometrial basal layer tight coordination between these signaling pathways and ovarian\nand the myometrium, which are absent from endometrial biop- hormones39,40. NOTCH inhibitors were found to promote the gensies. To improve the temporal resolution of the functional endo- eration of ciliated cells in fallopian tube41 and endometrial organmetrial layer, we have combined our dataset with another recent oids42,43. We also show that NOTCH-inhibited secretory cells express\nsingle-cell atlas of endometrial biopsies22. By integrating these two lower amounts of uterine milk proteins. Using single-cell mapping,\ndatasets, we have revealed other cell states, including a population we pinpoint the effect of NOTCH to early ciliary differentiation, as\nof fibroblasts (fibroblasts C7) restricted to the basal layer. Second, suggested by the strong effect NOTCH inhibition has on preciliated\nour strategy of spatial mapping with 10x Genomics Visium and cells. Thus, we demonstrate opposing roles of WNT and NOTCH\nquantitative multiplexed smFISH techniques allows us to determine in shaping distinct endometrial epithelial lineages. In vivo, this is\nthree-dimensional cellular arrangements described in transcrip- regulated by the boundaries set by the localization of distinct cellular\ntomic analysis of cell isolates. By mapping cells into tissues with populations in the lumenal versus glandular microenvironments.\nour deconvolution method18, we allocated epithelial cells into the Our integrative map of cellular profiles of the normal endothree main endometrial layers: lumenal, functional and basal. Our metrium will serve as an essential reference for the study of\nexpanded CellPhoneDB v.3.0 analysis framework dissects the cell many neglected endometrial disorders. Organoids, which can be\n\n1710 Nature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\nbiobanked, have been established from samples of endometrio- 21. Rozenblatt-Rosen, O., Stubbington, M. J. T., Regev, A. & Teichmann, S. A.\nsis and endometrial adenocarcinomas that resemble the original The Human Cell Atlas: from vision to reality. Nature 550, 451–453 (2017).\n 22. Wang, W. et al. Single-cell transcriptomic atlas of the human endometrium\ntumors10,11,35,44. Our study shows that the combination of genomics, during the menstrual cycle. Nat. Med. 26, 1644–1653 (2020).\nimaging and organoids can create a robust platform for studying 23. Vento-Tormo, R. et al. Single-cell reconstruction of the early maternal–fetal\nendometrial physiology. This will have a wide-ranging impact on interface in humans. Nature 563, 347–353 (2018).\nwomen’s health and reproductive medicine. 24. Hapangama, D. K. et al. Abnormally located SSEA1+/SOX9+ endometrial\n epithelial cells with a basalis-like phenotype in the eutopic functionalis layer\n may play a role in the pathogenesis of endometriosis. Hum. Reprod. 34,\nOnline content 56–68 (2019).\nAny methods, additional references, Nature Research report- 25. Tempest, N., Baker, A. M., Wright, N. A. & Hapangama, D. K. Does human\ning summaries, source data, extended data, supplementary infor- endometrial LGR5 gene expression suggest the existence of another\nmation, acknowledgements, peer review information; details of hormonally regulated epithelial stem cell niche? Hum. Reprod. 33, 1052–1062\n (2018).\nauthor contributions and competing interests; and statements of 26. Barker, N. et al. Lgr5+ve stem cells drive self-renewal in the stomach and build\ndata and code availability are available at https://doi.org/10.1038/ long-lived gastric units in vitro. Cell Stem Cell 6, 25–36 (2010).\ns41588-021-00972-2. 27. Jaks, V. et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat.\n Genet. 40, 1291–1299 (2008).\nReceived: 13 February 2021; Accepted: 18 October 2021; 28. Barker, N. et al. Lgr5+ve stem/progenitor cells contribute to nephron\nPublished online: 2 December 2021 formation during kidney development. Cell Rep. 2, 540–552 (2012).\n 29. Ng, A. et al. Lgr5 marks stem/progenitor cells in ovary and tubal epithelia.\n Nat. Cell Biol. 16, 745–757 (2014).\nReferences 30. Cancer Genome Atlas Research Network et al. Integrated genomic\n1. Garrido-Gomez, T. et al. Defective decidualization during and after severe characterization of endometrial carcinoma. Nature 497, 67–73 (2013).\n preeclampsia reveals a possible maternal contribution to the etiology. Proc. 31. Gabriel, M. et al. A relational database to identify differentially expressed\n Natl Acad. Sci. USA 114, E8468–E8477 (2017). genes in the endometrium and endometriosis lesions. Sci. Data 7, 284 (2020).\n2. Rabaglino, M. B. & Conrad, K. P. Evidence for shared molecular pathways of 32. Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. &\n dysregulated decidualization in preeclampsia and endometrial disorders Saez-Rodriguez, J. Benchmark and integration of resources for the estimation\n revealed by microarray data integration. FASEB J. 33, 11682–11695 (2019). of human transcription factor activities. Genome Res. 29, 1363–1375 (2019).\n3. Salker, M. S. et al. Deregulation of the serum- and glucocorticoid-inducible 33. Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R.\n kinase SGK1 in the endometrium causes reproductive failure. Nat. Med. 17, CellPhoneDB: inferring cell–cell communication from combined expression\n 1509–1513 (2011). of multi-subunit ligand–receptor complexes. Nat. Protoc. 15, 1484–1506\n4. Cancer Research UK. Uterine cancer risk. https://www.cancerresearchuk.org/ (2020).\n health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/ 34. Tóth, B., Ben-Moshe, S., Gavish, A., Barkai, N. & Itzkovitz, S. Early\n risk-factors#heading-Zero (2018). commitment and robust differentiation in colonic crypts. Mol. Syst. Biol. 13,\n5. Houshdaran, S. et al. Steroid hormones regulate genome-wide epigenetic 902 (2017).\n programming and gene transcription in human endometrial cells with 35. Boretto, M. et al. Patient-derived organoids from endometrial disease capture\n marked aberrancies in endometriosis. PLoS Genet. 16, e1008601 (2020). clinical heterogeneity and are amenable to drug screening. Nat. Cell Biol. 21,\n6. Martin, R. D. The evolution of human reproduction: a primatological 1041–1051 (2019).\n perspective. Am. J. Phys. Anthropol. Suppl. 45, 59–84 (2007). 36. Fitzgerald, H. C., Dhakal, P., Behura, S. K., Schust, D. J. & Spencer, T. E.\n7. Emera, D., Romero, R. & Wagner, G. The evolution of menstruation: a new Self-renewing endometrial epithelial organoids of the human uterus. Proc.\n model for genetic assimilation: explaining molecular origins of maternal Natl Acad. Sci. USA 116, 23132–23142 (2019).\n responses to fetal invasiveness. Bioessays 34, 26–35 (2012). 37. La Manno, G. et al. Molecular diversity of midbrain development in mouse,\n8. Brosens, J. J., Parker, M. G., McIndoe, A., Pijnenborg, R. & Brosens, I. A. A human, and stem cells. Cell 167, 566–580.e19 (2016).\n role for menstruation in preconditioning the uterus for successful pregnancy. 38. Miller, A. J. et al. In vitro and in vivo development of the human airway at\n Am. J. Obstet. Gynecol. 200, 615.e1–615.e6 (2009). single-cell resolution. Dev. Cell 53, 117–128.e6 (2020).\n9. Hempstock, J., Cindrova-Davies, T., Jauniaux, E. & Burton, G. J. Endometrial 39. Tulac, S. et al. Dickkopf-1, an inhibitor of Wnt signaling, is regulated by\n glands as a source of nutrients, growth factors and cytokines during the first progesterone in human endometrial stromal cells. J. Clin. Endocrinol. Metab.\n trimester of human pregnancy: a morphological and immunohistochemical 91, 1453–1461 (2006).\n study. Reprod. Biol. Endocrinol. 2, 58 (2004). 40. Wang, Y. et al. Progesterone inhibition of Wnt/β-catenin signaling in normal\n10. Turco, M. Y. et al. Long-term, hormone-responsive organoid cultures of endometrium and endometrial cancer. Clin. Cancer Res. 15, 5784–5793 (2009).\n human endometrium in a chemically defined medium. Nat. Cell Biol. 19, 41. Kessler, M. et al. The Notch and Wnt pathways regulate stemness and\n 568–577 (2017). differentiation in human fallopian tube organoids. Nat. Commun. 6, 8989\n11. Boretto, M. et al. Development of organoids from mouse and human (2015).\n endometrium showing endometrial epithelium physiology and long-term 42. Haider, S. et al. Estrogen signaling drives ciliogenesis in human endometrial\n expandability. Development 144, 1775–1786 (2017). organoids. Endocrinology 160, 2282–2297 (2019).\n12. Cindrova-Davies, T. et al. Menstrual flow as a non-invasive source of 43. Cochrane, D. R. et al. Single cell transcriptomes of normal endometrial\n endometrial organoids. Commun. Biol. 4, 651 (2021). derived organoids uncover novel cell type markers and cryptic differentiation\n13. Ståhl, P. L. et al. Visualization and analysis of gene expression in tissue of primary tumours. J. Pathol. 252, 201–214 (2020).\n sections by spatial transcriptomics. Science 353, 78–82 (2016). 44. Girda, E., Huang, E. C., Leiserowitz, G. S. & Smith, L. H. The use of\n14. Rodriques, S. G. et al. Slide-seq: a scalable technology for measuring genome- endometrial cancer patient-derived organoid culture for drug sensitivity\n wide expression at high spatial resolution. Science 363, 1463–1467 (2019). testing is feasible. Int. J. Gynecol. Cancer 27, 1701–1707 (2017).\n15. Vickovic, S. et al. High-definition spatial transcriptomics for in situ tissue\n profiling. Nat. Methods 16, 987–990 (2019). Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in\n16. Stickels, R. R. et al. Highly sensitive spatial transcriptomics at near-cellular published maps and institutional affiliations.\n resolution with Slide-seqV2. Nat. Biotechnol. https://doi.org/10.1038/\n s41587-020-0739-1 (2020). Open Access This article is licensed under a Creative Commons\n17. Critchley, H. O. D., Maybin, J. A., Armstrong, G. M. & Williams, A. R. W. Attribution 4.0 International License, which permits use, sharing, adap-\n Physiology of the endometrium and regulation of menstruation. Physiol. Rev. tation, distribution and reproduction in any medium or format, as long\n 100, 1149–1179 (2020). as you give appropriate credit to the original author(s) and the source, provide a link to\n18. Kleshchevnikov, V. et al. Comprehensive mapping of tissue cell architecture the Creative Commons license, and indicate if changes were made. The images or other\n via integrated single cell and spatial transcriptomics. Preprint at bioRxiv third party material in this article are included in the article’s Creative Commons license,\n https://doi.org/10.1101/2020.11.15.378125 (2020). unless indicated otherwise in a credit line to the material. If material is not included in\n19. Andersson, A. et al. Single-cell and spatial transcriptomics enables the article’s Creative Commons license and your intended use is not permitted by statu-\n probabilistic inference of cell type topography. Commun. Biol. 3, 565 (2020). tory regulation or exceeds the permitted use, you will need to obtain permission directly\n20. Cable, D. M. et al. Robust decomposition of cell type mixtures in spatial from the copyright holder. To view a copy of this license, visit http://creativecommons.\n transcriptomics. Nat. Biotechnol. https://doi.org/10.1038/s41587-021-00830-w org/licenses/by/4.0/.\n (2021). © The Author(s) 2021, corrected publication 2022\n\n\nNature Genetics | VOL 53 | December 2021 | 1698–1711 | www.nature.com/naturegenetics 1711\n\nArticles NaTurE GEnETICS\n\nMethods 10) clusters serving as the basis for the distribution and the statistical significance\nUterine tissue retrieval. Full-thickness uterine wall samples were obtained from analysis described in ref. 50, with Bonferroni for FDR correction and a significance\ndeceased transplant organ donors (A13, A30) after ethical approval (reference threshold of 0.01. In the organoid samples, additional cells were identified as\n15/EE/0152, East of England–Cambridge South Research Ethics Committee) and doublets by Souporcell52 when multiple genotypes were found in single droplets.\ninformed consent from the donor families. Uterus was removed within 1 h of After filtering out cells with fewer than 500 genes and more than 15%\ncirculatory arrest. mitochondrial reads (20% for organoids), samples were integrated using scVI53\n Full-thickness uterine wall samples were collected from four women during (v.0.6.5). While the raw count matrices were used for single cells, the counts from\nautopsy (Trv2, Trv3, Trv4 and Trv5). All four individuals died of noncancer-related single nuclei were denoised from ambient RNA before the manifold identification.\ncauses, either traumatic injuries (Trv2, Trv3 and Trv4) or brain edema (Trv5). For that task, decontX54 (under the ‘celda’ R package v.1.5.11) was used on each\nSamples were collected within less than 10 h of death (postmortem interval was sample separately. We then excluded cell cycling genes from G2/M and S phases\n5, 2, 4 and 6 h, respectively). Once collected, all tissue biopsies were snap-frozen listed inside the Seurat package55. For the in vivo dataset, the expression levels of\nin liquid nitrogen and subsequently stored at −80 °C. The use of these tissues was the 5,000 genes that were identified by the scVI native method were modeled by its\napproved by the London, Surrey Research Ethics Committee (REC reference 17/ generative model with 64 latent variables for 500 iterations. Epithelial, endothelial\nLO/1801, 26/10/2017). and immune cells were subsequently reanalyzed separately by using 16 latent\n Endometrial biopsies were obtained from live donors with written, informed variables. The resulting latent variables were used for neighbor identification for\nconsent from all participants from multiple centers. Leiden clustering56 and uniform manifold approximation and projection (UMAP)\n Endometrial biopsies for sequencing were obtained from individuals recruited visualization. The resulting clusters specific to a single donor, or that had lower\nfrom Newcastle Upon Tyne Hospitals after ethical approval (reference 16/NE/0167, numbers of genes expressed or a lower percentage of mitochondrial expression,\nNorth East–Newcastle & North Tyneside 1 Research Ethics Committee). were excluded. In the epithelial and immune cell reanalysis, cells exhibiting high\n Proliferative endometrial biopsies for deriving organoids were obtained doublet scores were excluded, and epithelial cells were subsampled to balance\nfrom Addenbrooke’s Hospital under ethical approval from the East of England– donor contribution (Annotation of organoid data using scRNA-seq in vivo dataset\nCambridge South Research Ethics Committee (08/H0305/40). reference).\n Endometrial scratch samples from secretory-phase endometrium for deriving\norganoids were obtained from Bourne Hall Clinic under ethical approval from the Annotation of scRNA-seq datasets. Identification and labeling of the major\nEast of England–Central Research Ethics Committee for the ‘Biology of the Human cell types in the in vivo dataset was by manual inspection of marker genes and\nUterus in Pregnancy and Disease Tissue Bank’ run by the Centre for Trophoblast interpretation of these based on the literature. Cluster-specific marker genes\nResearch (17/EE/0151). were defined using two approaches. To account for the donor effect, we first used\n Endometrial biopsies were obtained using a disposable endometrial cell DEseq2 (ref. 57), where cells were aggregated into in silico mini-bulks by summing\nsampler, starting from the uterine fundus and moving downward to the internal the raw expression of single cells separately according to their donor origin. Every\ncervical ostium. None of the participants were on hormonal treatments for at least cell-type-specific mini-bulk was compared against a matched mini-bulk that\n3 months before the procedure. corresponded to all other cells from the same donor; however, such mini-bulk\n Endometrial tissues were staged based on standard histological criteria. pairs defined by aggregating less than ten cells were excluded (for example,\n Tissue dissociation for all fresh tissues was conducted within 24 h of tissue clusters associated with a specific menstrual stage). Secondly, the Wilcoxon test\nretrieval in a two-step digestion protocol. Briefly, endometrial tissue was treated was used to report genes that were differentially expressed. To account for change\nwith collagenase to retrieve the stromal fraction (step 1)45. After filtering, pieces of sequencing depth, cells were partitioned into four groups corresponding to the\nof tissue retained on the 100-µm filter were treated with trypsin to enrich for the quartiles of the sequencing depth of cells considered (independent of donors),\nepithelial fraction (step 2)46. Nuclei were released via Dounce homogenization as and the four resulting Z-scores were combined. P values were adjusted with the\ndescribed previously47. Benjamini–Hochberg method.\n For each cell, we estimated the cell cycle phase (G1, S or G2/M) based on its\nEndometrial organoid cultures. Endometrial organoids were grown as previously expression of G2/M and S phase markers, following the method described in ref. 58\ndescribed10. Briefly, organoids were cultured at 37 °C in a humidified atmosphere of and implemented in Scanpy score_genes_cell_cycle function.\n5% CO2. The medium was refreshed every 2–3 d, and the organoids were passaged\nat an average ratio of 1:3 every 5–7 d. The organoid suspension was centrifuged Efficiency of organoid differentiation. To identify clusters predominantly\nfor 6 min at 600g between passaging steps. The passaged organoid pellet was appearing in organoid cultures upon treatment with WNT or NOTCH inhibitors,\nresuspended in 25-μl ice-cold Matrigel (Corning, 356231) droplets, plated in a we evaluated the proportion of cells in each cluster coming from the organoids\n48-well plate (Costar, 3548), allowed to solidify at 37 °C for 15–30 min and covered with and without inhibitors using Fisher’s exact test. Odds ratios were computed\nwith 250 μl of endometrial organoid ExM. Components of ExM for culturing against the control organoids (grown with no inhibitors) at the matched time\nhuman endometrial organoids are available in Supplementary Table 14. points on a per-genotype basis. In addition, the robustness of the observed effect\n was evaluated using a paired t-test that compares these fractions of cells from\nHormonal stimulation and inhibition experiment of endometrial organoids. organoids that were treated with inhibitor with their respective controls.\nEndometrial organoids were stimulated with hormones and treated with NOTCH\nγ-secretase inhibitors (DBZ, Tocris 4489 and DAPT, Tocris 2634) as well as WNT Annotation of organoid data using scRNA-seq in vivo dataset reference. To\ninhibitors (tankyrase inhibitor XAV939, Tocris 3748 and porcupine inhibitor identify transcriptomic similarities with the in vivo scRNA-seq epithelial subset,\nIWP-2, Tocris 3533) for 6 d. First, 10,000 single cells were plated per 25-μl Matrigel we used a regularized logistic regression approach. To best link variation in gene\ndroplet into a 48-well plate with ExM supplemented with Rho kinase inhibitor expression in organoids to changes in donors with known stages of the menstrual\n(Y-27632-CAS 146986-50-7) and CHIR 99021. At 10 d after plating, organoids were cycle, we subsampled the in vivo epithelial cells up to 1,000 cells per donor,\nprimed with 10 nM estrogen (E2) and treated with NOTCH and WNT inhibitors which balances the cell number representing each stage. To limit the influence of\n(20 μM DAPT, 1 μM DBZ, 2 μM IWP-2, 2 μM XAV939 in the ExM). R-spondin-1, cell cycle, we excluded the SOX9 proliferative cluster composed of a majority of\na WNT signaling activator, was depleted from the ExM in the conditions where cells at G2/M or S phase, and also excluded the G2/M and S genes from Seurat.\nWNT inhibitors were used. After 48 h, they were stimulated with 10 nM E2, 1 μM Subsequently, we subset both datasets to their shared highly variable genes and\nprogesterone (P4), 100 μg ml−1 cAMP and 20 ng ml−1 prolactin while still being further prune half of remaining genes that are not cell-type-specific according\ntreated with NOTCH and WNT inhibitors (20 μM DAPT, 1 μM DBZ, 2 μM IWP- to three heuristic measures (fold-increase, fold-increase × fraction-positive,\n2, 2 μM XAV939). Conditions in which (1) inhibitors but no hormones, (2) no fold-increase × fraction-positive0.5)59. Gene expression was log-transformed and\ninhibitors but hormones and (3) no inhibitors and no hormones were added were normalized by the maximum RNA expression for both datasets. The model was\nused as controls. trained with the in vivo epithelial identities, with 10,000 iterations, and used to\n classify organoid cells. To visualize results as radial projection we followed La\nDoublet detection, alignment of data across different batches and clustering of Manno et al.37, where the overlaid position of each cell corresponds to the weighted\nscRNA-seq data. The 10x Genomics scRNA-seq data were analyzed with Scanpy48, average of radially balanced unitary vectors (each pointing toward a different\nwith the pipeline following their recommended standard practices. In addition, we corner of a regular polygon), where the weight is each posterior probability of a cell\nimplemented a number of enhancements described below. to belong to a given cell type. The latter transformation is a softmax function where\n Individual samples of single cells or single nuclei were initially analyzed each component is multiplied by 15 before being exponentiated.\nseparately before being batch corrected into an integrated dataset and had two-step\ndiffusion doublet identification performed49,50. The first step was performed with Annotation of snRNA-seq using scRNA-seq in vivo dataset as a reference.\nScrublet51 (v.0.2.1) on a per-sample basis, with the scores diffused by overclustering A quantitative measure of the similarity was reported by evaluating the cosine\nthe cells and reporting each cluster’s median value. Doublets were identified from distance from in vivo single nuclei to the centroids of expression defined by the\na distribution of these scores centered at the median and using a mean absolute cell-type clusters identified in in vivo single cells, where each vector compared\nstandard deviation estimate, with statistically significant cells after FDR correction either contains expression of all selected genes in a single cell or their respective\nflagged as doublets. The second diffusion step takes place in a joint multi-sample mean expression for a given cell-type cluster. Results were visualized with a radial\nmanifold, with the frequency of identified doublets in granular (Leiden resolution projection as described previously by La Manno et al.37.\n\n\n Nature Genetics | www.nature.com/naturegenetics\n\nNaTurE GEnETICS Articles\nTrajectory analysis of organoid data. To identify the branching point where approach to v.3.0 (ref. 33). First, we retrieved the interacting pairs of ligands and\ncells commit to a ciliated or secretory fate, we first identified cell clusters in the receptors satisfying the following criteria: (1) all the members were expressed in at\norganoid cultures. Then, we used Palantir60 (v.1.0.0) on cells from the clusters that least 10% of the cells in the cluster under consideration and (2) at least one of the\ndid exhibit a mean expression level of the progesterone receptor higher than 0.2. A members in the ligand or the receptor is a differentially expressed gene (Wilcoxon\nrandomly selected cell corresponding to proliferating cells at day 2 was selected as test; Annotation of scRNA-seq datasets). To account for the distinct temporal\na cell of origin. and spatial location of cells (that is, microenvironment), we further classified the\n epithelial interactions based on (1) the phase of the menstrual cycle where cell\nCellular signal analysis. Tumor bulk transcriptomes for endometrioid (430 subsets coexist and (2) their location in the three main endometrial layers (luminal,\nsamples) and serous (112 samples) endometrial adenocarcinoma were downloaded glandular and basal) according to cell2location (ref. 18).\nfrom TCGA. Cellular signal analysis was then applied61 to identify the major To account for the complexity of WNT cell–cell signaling, several ligands and\ntranscriptional programs used by tumor cells based on our single-cell endometrial functional heteromeric receptors were further curated manually and re-annotated\natlas. This method fits the raw bulk messenger RNA counts to a weighted linear in the CellPhoneDB database (Supplementary Table 16).\ncombination of transcriptomic signals derived from reference single-cell data.\nTo limit the effect of the cell cycle, we only included cells in the G1 phase and Image stitching and manual annotation of selected glands.\nexcluded a proliferative SOX9 cluster. Proportions of epithelial-derived signals Confocal image stacks were stitched as two-dimensional maximum\nin the bulk samples were computed as the fraction of samples for which signals intensity projections using the BIOP Perkin Elmer Acapella Stitcher\n(exposures) derived from an epithelial cell cluster exceed the intercept term of (EPFL, Lausanne; https://www.perkinelmer.com/PDFs/downloads/\nthe model. Clinical data associated with the samples that exhibited exposure TCH-Workflows-In-Depth-High-Content-Analysis-Operetta.pdf).\nfor SOX9+LGR5+ or SOX9+LGR5− above the intercept value were further\ninvestigated; we used the Kruskal–Wallis test to confirm that SOX9+LGR5+ smFISH quantification. RNA spot quantification of smFISH targeting WNT7A\nsignature contribution (exposure) in tumors differs in different cancer stages (as and NOTCH2 was achieved with a three-step process:\ndefined in TCGA clinical data), and used the Wilcoxon test and t-test to assess the Step 1. Segmenting glands within the tissue. Ilastik65 was used to train a\nsignificance of the increase in exposure noted in later stages of cancer, as well as random-forest-based pixel classifier to detect valid gland areas based on the\nseveral clinical data (Supplementary Table 3). Nuclear-DAPI channel and the Gland-EPCAM (IHC) channel. Three rounds of\n ilastik classification were used to achieve adequate rejection of off-target signal to\nLocation of cell types in Visium data. To spatially map cell types defined by segment only the glands.\nscRNA-seq analysis within the Visium spatial transcriptomics data, we used Step 2. Segmenting RNA spots within the glands. Another ilastik pixel classifier\ncell2location (ref. 18) (v.0.5-alpha). Briefly, cell2location decomposes multi-cell was used on the spot channels to segment areas that corresponded to genuine spots\nspatial transcriptomics data into cell-type abundance estimates in a spatially that were situated in the glands segmented in step 1. The spots were verified by\nresolved manner. First, the model derives expression signatures of cell types by only including spots visible in one channel only. This was done to remove blood\ncalculating average expression counts of each gene in each cell type in the raw inclusions, which gave a confounding signal across multiple channels.\ncount scRNA-seq data, selecting genes expressed in at least three cells. Next, Step 3. The edge of the lumen was manually annotated using napari66. The\nto obtain cell-type locations, the model performs a hierarchical non-negative distance of each pixel on the image was calculated to the nearest point on the\ndecomposition of the gene expression profiles at spatial locations (spots with lumen edge. Then the total fluorescence intensity was measured for spots in glands\nmultiple cells) into the reference signatures. Each Visium section was analyzed and binned into intervals of distance away from the lumen. The gland area was\nseparately with parameters set to default values, except train_args = ‘n_iter’: also calculated for each distance interval. The spot fluorescence was divided by the\n30,000; posterior_args = ‘n_samples’: 1,000; model_kwargs = ‘cell_number_prior’: gland interval to give a value of spot intensity that was normalized by area.\n{‘cells_per_spot’: 8, ‘factors_per_spot’: 4}; and ‘gene_level_prior’: {‘mean’: 1/2, ‘sd’:\n1/4, ‘mean_var_ratio’: 1}. We visualize the absolute amount of mRNA contributed Reporting Summary. Further information on research design is available in the\nby each cell population to each spot. We used a 5% percentile of the posterior Nature Research Reporting Summary linked to this article.\ndistribution of this parameter (mRNA counts), representing the number of mRNA\nmolecules confidently assigned to each cell type. Data availability\n Datasets were uploaded into ArrayExpress under accession numbers E-MTAB-10287\nClustering of spots. Visium data were processed using Scanpy48 following the (scRNA-seq in vivo), E-MTAB-9260 (Visium in vivo) and E-MTAB-10283\nrecommended tutorial with normalization using a scaling factor of 10,000; log (scRNA-seq in vitro). snRNA-seq in vivo data were uploaded into the European\ntransformation; variable gene detection with ‘Seurat’ flavor; principal-component Genome-phenome Archive; EGAD00001007909. Requests for data access should be\nanalysis (PCA); neighborhood graph building; and UMAP calculation. Each sent directly to the Data Access Committee of this work: datasharing@sanger.ac.uk\nsample was analyzed independently. (https://ega-archive.org/datasets/EGAD00001007909). Tumor bulk transcriptomes\n Clusters were defined by the Louvain algorithm and assigned as myometrium for endometrioid and serous endometrial adenocarcinomas were downloaded from\nor endometrium based on visual inspection of the H&E image of the tissue TCGA. Additional single-cell transcriptomes of ten endometrial biopsies were\naligned with each spot. The cluster of spots corresponding to epithelial cells in the downloaded from the Gene Expression Omnibus with GSE111976 (ref. 22). Processed\nendometrium for sample A30, 152807 slide, was further clustered using the same matrices can be accessed and downloaded from www.reproductivecellatlas.org.\napproach. One of the spot subpopulations was excluded due to the low percentage Image datasets are available at the EMBL-EBI BioImage Archive under accession\nof epithelial cells in the spot after visual inspection. The other ‘epithelial’ spot number S-BIAD190. Data availability includes all datasets in the manuscript. Source\nsubpopulations were labeled based on the endometrial layer in which they were data are provided with this paper.\nfound—basal, lumenal and glandular.\n Differentially expressed genes in each subpopulation of ‘epithelial’ spots were\ncalculated using the limma R package62. Code availability\n Code is available at https://github.com/Ventolab/UHCA. Source code and tutorials\nCalculating TF activities. TF activities were estimated via the combined for CellPhoneDB v.3 are available at https://github.com/Ventolab/CellphoneDB.\nexpression levels of their targets. Target genes were retrieved from Dorothea32,\nwhere TF–target relationships are scored from A to E, with decreasing confidence. References\nHere we updated Dorothea regulons as follows: first, synonymous gene names 45. Vento-Tormo, R. & Hoo, R. Endometrium dissociation with collagenase.\nwere corrected; second, bona fide TF–target relationships manually curated from protocols.io https://doi.org/10.17504/protocols.io.76thren (2019).\nUniprot were added as a new curated source; third, signed and curated interactions 46. Hoo, R. & Vento-Tormo, R. Endometrium dissociation with trypsin.\nwere upgraded to score B; fourth, TRRUST63 curated interactions were updated to protocols.io https://doi.org/10.17504/protocols.io.72dhqa6 (2020).\nv.2_20180416 version and signed interactions supported by more than one PubMed 47. Krishnaswami, S. R. et al. Using single nuclei for RNA-seq to capture the\nsource were upgraded to A; and, finally, we created a new category (AA) for the transcriptome of postmortem neurons. Nat. Protoc. 11, 499–524 (2016).\nmost trustable TF–target interactions that were either detected by all approaches or 48. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene\nin more than two curated resources. For each TF, we used the highest scored set of expression data analysis. Genome Biol. 19, 15 (2018).\ntargets with at least ten target genes, as in the original publication32. 49. Pijuan-Sala, B. et al. A single-cell molecular map of mouse gastrulation and\n Next, we estimated TF activities by performing a Gene Set Enrichment early organogenesis. Nature 566, 490–495 (2019).\nAnalysis (GSEA)-like analysis of the gene expression signatures of each cluster 50. Popescu, D.-M. et al. Decoding human fetal liver haematopoiesis. Nature 574,\nresulting from the Wilcoxon test (Annotation of scRNA-seq datasets) with the 365–371 (2019).\nmsVIPER function in the Viper R package64 v.1.22.0. New regulons are available in 51. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification\nSupplementary Table 15. of cell doublets in single-cell transcriptomic data. Cell Syst. 8, 281–291.e9\n (2019).\nCellPhoneDB v.3.0. To study the interactions between epithelial and other cell 52. Heaton, H. et al. Souporcell: robust clustering of single-cell RNA-seq data by\npopulations identified in our endometrial samples, we updated our CellPhoneDB genotype without reference genotypes. Nat. Methods 17, 615–620 (2020).\n\n\nNature Genetics | www.nature.com/naturegenetics\n\nArticles NaTurE GEnETICS\n53. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative families for granting access to the tissue samples as well as the Specialist Nurses on Organ\n modeling for single-cell transcriptomics. Nat. Methods 15, 1053–1058 (2018). Donation (SNODs). This work was supported by the Wellcome Trust grant ‘Wellcome\n54. Yang, S. et al. Decontamination of ambient RNA in single-cell RNA-seq with Strategic Support Science award’ (grant no. 211276/Z/18/Z); the Wellcome Sanger core\n DecontX. Genome Biol. 21, 57 (2020). funding (grant no. WT206194); the Wellcome Trust joint investigator award (grant\n55. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating no. 200841/Z/16/Z); the MRC Human Cell Atlas (grant no. MR/S036350/1); the Royal\n single-cell transcriptomic data across different conditions, technologies, and Society Dorothy Hodgkin Fellowship (grant no. DH160216); the Royal Society Research\n species. Nat. Biotechnol. 36, 411–420 (2018). Grant (grant no. RG93116); the Centre for Trophoblast Research; the European Union’s\n56. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: Horizon 2020 research and innovation program under grant agreement no. 874867;\n guaranteeing well-connected communities. Sci. Rep. 9, 5233 (2019). the European Research Council grant no. 853546, and the Chan Zuckerberg Initiative\n57. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and DAF, an advised fund of Silicon Valley Community Foundation (grant no. 2018-190766/\n dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). RG98793). L.M. is a recipient of the Jean Shank/Pathological Society of Great Britain and\n58. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic Ireland Intermediate Research Fellowship (grant reference no. 1175).\n melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).\n59. Marques, S. et al. Oligodendrocyte heterogeneity in the mouse juvenile and\n adult central nervous system. Science 352, 1326–1329 (2016). Author contributions\n60. Setty, M. et al. Characterization of cell fate probabilities in single-cell data R.V.-T. and M.Y.T. designed and supervised the experiments and analysis with\n with Palantir. Nat. Biotechnol. 37, 451–460 (2019). contributions from S.A.T. and O.A.B.; R.V.-T. and C.S.-S. performed sampling and\n61. Young, M. D. et al. Single cell derived mRNA signals across human kidney library prep with help from L.M., R.H., T.P., E.P., M.D., K.T.M., P.A., M.R.S. and K.S.-P.\n tumors. Nat. Commun. 12, 3896 (2021). L.G.-A., L.-F.H. and R.V.-T. performed computational analyses with contribution from\n62. Ritchie, M. E. et al. limma powers differential expression analyses for V.L., H.M., K.P., J.P., S.v.D., M.P., V.Y.K., V.K. and A.A. K.R., B.W., E.T., T.L., K.K., A.T.,\n RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). C.I.M., V.V. and O.A.B. performed and analyzed the smFISH; L.G. and C.L. performed\n63. Han, H. et al. TRRUST v2: an expanded reference database of human and immunohistochemistry; K.N., R.C.F. and M.Y.T. performed the organoid experiments;\n mouse transcriptional regulatory interactions. Nucleic Acids Res. 46, L.M., M.J.-L., L.C. and A.M. provided pathological expertise; R.V.-T., A.M. and M.Y.T.\n D380–D386 (2018). wrote the manuscript with contributions from L.G.-A., K.R., K.N., L.M., O.A.B. and\n64. Alvarez, M. J. et al. Functional characterization of somatic mutations in S.A.T. All authors read and approved the manuscript.\n cancer using network-based inference of protein activity. Nat. Genet. 48,\n 838–847 (2016). Competing interests\n65. ilastik release 1.3.3post3 (accessed 1 December 2020); https://www.ilastik.org/ In the past 3 years, S.A.T. has worked as a consultant for Genentech, Roche and\n index.html Transition Bio, is a remunerated member of the scientific advisory boards of Biogen,\n66. napari release 0.4.2 (accessed 1 December 2020); https://napari.org/ GlaxoSmithKline, Foresite Labs and Qiagen and is an equity holder of Transition Bio.\n The remaining authors declare no competing interests.",
      "rationale": "heuristic fallback"
    }
  ],
  "created_at": "2026-02-14T07:39:53.554656+00:00"
}